期刊文献+

雌雄激素受体与膀胱癌预后的关系 被引量:3

The Relationship between Estrogen and Androgen Receptors and Prognosis of Bladder Transitional Cell Carcinoma
暂未订购
导出
摘要 采用荧光组织化学法测定了 89例膀胱移行细胞癌雌雄激素受体的表达 ,获长期随访的 77例中有 32例复发 ,复发率为 41.5 6 %。采用乘积限法计算受体表达阳性各组及阴性组肿瘤复发率并进行比较。结果提示膀胱癌复发率随雌激素受体表达增多有下降趋势 ,但无统计学显著差异 ;雄激素受体表达阳性与否亦与肿瘤复发率无关。 Estrogen receptor(ER) and Androgen receptor(AR) assays were performed with fluorescent histochemical method in 89 cases of bladder carcinoma.77 cases were followed up for at leazt six years.The tumor recurrence occurred in 32(41.56%). Product limit estimates were used to calculate the recurrence rate.The results showed: there was not statistic difference of recurrence rate between ER positive and negative groups. There wasn’t either statistic difference of recurrence rate between AR positive and negative groups.
出处 《医学新知》 CAS 2000年第2期62-64,共3页 New Medicine
关键词 膀胱癌 复发 性激素受体 预后 Bladder neoplasm Carcinoma Recurrence Hormone Receptor
  • 相关文献

参考文献3

  • 11,LaorE.Sex-dependentvariationsinthenaturalhistoryoftransitionalcellcarcinomaofbladder.Urology,1984,(3):237
  • 2李世文 邓显昭 唐孝达等.膀胱移行细胞癌雄激素受体研究(摘要)[J].中华泌尿外科杂志,1993,14(7):363-363.
  • 33,LaorE.Androgenreceptorsinbladdertumors.Urology,1985,25(2):161 (2000-04-11收稿)

同被引文献31

  • 1武文森,尹克铮.雌激素在MNU诱导大鼠膀胱肿瘤的抑癌作用及治疗膀胱癌的实验研究[J].肿瘤防治研究,1996,23(1):4-7. 被引量:7
  • 2韩瑞发,潘建刚.中国人群膀胱癌发病危险因素的Meta分析[J].中华泌尿外科杂志,2006,27(4):243-246. 被引量:22
  • 3程荣璇,王志华,王晓秋,胡闻,牛俊扬.膀胱癌的性激素受体检测及其意义[J].临床与实验病理学杂志,1996,12(4):326-328. 被引量:6
  • 4李同度,刘爱国,刘健民.ER、PR及β_2-MG检测在膀胱癌诊断、预后估计中的价值[J].肿瘤防治研究,1996,23(5):265-267. 被引量:3
  • 5Parkin MD, Bray F, Ferlay J, et al. Global Cancer Statistics. CA Cancer J Clin ,2005,55 (3) :74 - 108.
  • 6Solakidia S, Psarra AMG, Sekes CE. Differential subcellular distri- bution of estrogen receptor isoforms: Localization of ERc in the nu- cleoli and ER in the mirochordria of human osteosarcoma SaOS - 2 and hepatocarcinoma HepG2 cell lines. Biochimlca et Biophysica Ac- ta,2005,1745 (3) :382 - 392.
  • 7Koeh|er KF. Refections on the discovery and significance of estrogen receptor beta. Endocr Rev,2005 ,26 :465 - 478.
  • 8Liang S. Expression of ERa36, a novel variant of estrogen receptor ot , and resistance to tamoxifen treatment in breast cancer. J Clin 0n- col,2009,27 (21 ) :3423 - 3429.
  • 9Lee HY, Bai WL. Regulation of estrogen receptor nuclear export by ligand - induced and p38 - mediated receptor phosphorylation Molo- lecular Cell Biolgy . 2002,22(16) :5835 -5845.
  • 10Wu RC. Selective phosphorylations of the SRC - 3/AIBI coactivator integrate genomic reponses to muhiple cellularsignaling pathways. Mol CeLl,2004,15(2) :937 -949.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部